Drugs / TRX-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07526506 | Mar → Sep 2026 overdue | — | Traws Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06757738 | Aug 2024 → Jan 2025 | — | Traws Pharma, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-08 | Traws Pharma, Inc. | Results Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil trawspharma.com ↗
Topline data from the Phase 1 healthy volunteer study showed good overall tolerability and a pharmacokinetic profile that appears to support tivoxavir’s potential use as a one-time treatment for flu, including pandemic flu. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-08 | Traws Pharma, Inc. | Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil trawspharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06757738 ↗ |
| Route | Oral | “orally administered TRX-100” NCT06757738 ↗ |